RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Outlook Therapeutics Stock

Outlook Therapeutics P/S 2024

Outlook Therapeutics P/S

0

Ticker

OTLK

ISIN

US69012T2069

WKN

A2PF3C

As of Sep 30, 2024, Outlook Therapeutics's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Outlook Therapeutics P/S history

Outlook Therapeutics Aktienanalyse

What does Outlook Therapeutics do?

Outlook Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for eye diseases. The company was originally established in 2010 under the name Oncobiologics. Initially, the company focused on the development of biosimilar products to improve access and reduce costs of biologics. The goal was to bring cheaper alternatives to the market that were equivalent to approved original products. In 2018, the company decided to shift its focus to the development of ophthalmological therapeutics. Oncobiologics was rebranded as Outlook Therapeutics Inc, and the development of biosimilar products was discontinued. Instead, the company has since been focused on researching and developing eye therapies to provide better treatment options for patients with serious eye diseases. The business model of Outlook Therapeutics Inc is primarily based on the development and marketing of high-quality, patented medications for eye diseases. The company utilizes innovative technologies and research approaches to maximize the effectiveness and safety of its products. It works closely with leading experts and clinicians in the field of ophthalmology to ensure that the therapies meet the needs of patients. One of the key areas of Outlook Therapeutics Inc is the development of therapeutics for wet age-related macular degeneration (AMD). Wet AMD is a progressive degenerative eye disease that can lead to rapid vision deterioration. Currently, there are already various medications on the market for treating this condition. However, Outlook Therapeutics Inc is working on developing new therapeutics that have improved effectiveness, longer duration of action, and fewer side effects than existing medications. Another important area for the company is the development of therapeutics for diabetic macular edema, a disease that can occur in individuals with type 2 diabetes. The company is researching improved treatments for this condition, which can often lead to blindness. Outlook Therapeutics Inc offers a variety of products aimed at improving patients' visual capabilities. In addition to the aforementioned medications, the company also provides medication combinations and drugs with special active ingredients. Through continuous research and development, Outlook Therapeutics Inc constantly expands and optimizes its offerings to meet the needs of patients in the field of eye therapy. Overall, the business model of Outlook Therapeutics Inc is focused on advancing the research and development of new therapies for eye diseases. Through innovative technologies and collaboration with experts in the field of ophthalmology, the company aims to improve the quality of life for patients with severe eye diseases and provide them with better treatment options. Outlook Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Outlook Therapeutics's P/S Ratio

Outlook Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Outlook Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Outlook Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Outlook Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Outlook Therapeutics stock

What is the price-to-earnings ratio of Outlook Therapeutics?

The price-earnings ratio of Outlook Therapeutics is currently 0.

How has the price-earnings ratio of Outlook Therapeutics changed compared to last year?

The price-to-earnings ratio of Outlook Therapeutics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Outlook Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Outlook Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Outlook Therapeutics affect the company?

An increase in the price-earnings ratio of Outlook Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Outlook Therapeutics affect the company?

A decrease in the price-earnings ratio of Outlook Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Outlook Therapeutics?

Some factors that influence the price-earnings ratio of Outlook Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Outlook Therapeutics pay?

Over the past 12 months, Outlook Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Outlook Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Outlook Therapeutics?

The current dividend yield of Outlook Therapeutics is .

When does Outlook Therapeutics pay dividends?

Outlook Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Outlook Therapeutics?

Outlook Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Outlook Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Outlook Therapeutics located?

Outlook Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Outlook Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Outlook Therapeutics from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Outlook Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Outlook Therapeutics in the year 2023?

In the year 2023, Outlook Therapeutics distributed 0 USD as dividends.

In which currency does Outlook Therapeutics pay out the dividend?

The dividends of Outlook Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Outlook Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Outlook Therapeutics

Our stock analysis for Outlook Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Outlook Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.